A Study Of Prehabilitation In Patients With Multiple Myeloma Receiving CAR-T Therapy
Overview
Tab Title Description
Study type
InterventionalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Rochester, Minnesota: 25-001845
NCT ID: NCT07045727
Sponsor Protocol Number: 25-001845
About this study
The purpose of this study is to evaluate the feasibility and acceptability of a 6-week home-based virtual prehabilitation program with remote monitoring in 20 patients ≥60 years with relapsed/refractory (R/R) multiple myeloma (MM) scheduled to receive CAR-T therapy at Mayo Clinic – Rochester.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
Multiple Myeloma diagnosis
Females and males ≥60 years of age
ECOG score of <3
Scheduled for a CAR T Therapy transfusion
Apheresis date at least 7 days prior to date of enrollment
Primary hematologist attending physician clearance for exercise
Exclusion Criteria:
Females or males <60 years of age
Any hematological cancer other than multiple myeloma
Evidence of an absolute contraindication (eg, heart insufficiency >NYHA III or uncertain arrhythmia; uncontrolled hypertension; reduced standing or walking ability for exercise).
Other comorbidities that preclude participation in the exercise as deemed by physical therapist or PM&R physician.
Active infections, active bleeding disorders, and cytopenias at risk for further adverse events deemed by hematologist-oncologist
Note: Other protocol defined Inclusion/Exclusion Criteria may apply.
Eligibility last updated 02/25/2025. Questions regarding updates should be directed to the study team contact.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
Contact |
Rochester, Minn.
Mayo Clinic principal investigator Nadine Abdallah, M.D. |
Open for enrollment |
Contact information:
Cancer Center Clinical Trials Referral Office
(855) 776-0015
|
More information
Publications
Publications are currently not available